.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,174,975

« Back to Dashboard

Claims for Patent: 9,174,975

Title:Remedy for integration dysfunction syndrome
Abstract: The present invention provides a novel method for treatment of schizophrenia which can improve wide-ranging symptoms of schizophrenia, especially positive symptoms and negative symptoms without being accompanied by extrapyramidal symptoms, which comprises orally administering as an active compound (1R,2S,3R,4S)--N-[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-piperazinylme- thyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide or a pharmaceutically acceptable salt thereof (e.g., hydrochloride) at a daily dose of 5 mg to 120 mg once a day to a patient with schizophrenia, and a therapeutic agent to be used in the method.
Inventor(s): Nakamura; Mitsutaka (Osaka, JP), Ogasa; Masaaki (Osaka, JP), Sami; Shunsuke (Osaka, JP)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD (Osaka, JP)
Application Number:10/525,021
Patent Claims: 1. A method for treating the negative symptoms of schizophrenia and/or the cognitive dysfunction of schizophrenia in a patient, which comprises orally administering a once daily dose of 5 mg to 120 mg of the active compound: (1R,2S,3R,4S)--N[(1R,2R)-2-[4-(1,2-benzoisothiazol-3-yl)-1-pipe- razinylmethyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide of the formula (1): ##STR00005## or a pharmaceutically acceptable salt thereof to a patient suffering from negative symptoms of schizophrenia and/or cognitive dysfunction of schizophrenia.

2. The method of claim 1, which is a method for treating the negative symptoms of schizophrenia in a patient.

3. The method of claim 1, which is a method for treating the cognitive dysfunction of schizophrenia in a patient.

4. The method of claim 1, 2 or 3 wherein the pharmaceutically acceptable salt of said active compound is (1R,2S,3R,4S)--N-[(1R,2R)-2-[4-(1,2benzoisothiazol-3-yl)-1-piperazinylmet- hyl]-1-cyclohexylmethyl]-2,3-bicyclo[2.2.1]heptanedicarboxyimide hydrochloride.

5. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 20 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

6. The method of any one of claims 1, 4, 2 and 3, wherein said patient is in a chronic stage of schizophrenia, and wherein a once daily dose of 5 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

7. The method of any one of claims 1, 4, 2 and 3, wherein said patient is in an acute stage of schizophrenia, and wherein a once daily dose of 40 mg to 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

8. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 40 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

9. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

10. The method of any one of claims 1, 4, 2 and 3, wherein a once daily dose of 120 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.

11. The method of claim 6, wherein a once daily dose of 10 mg to 80 mg of said active compound or a pharmaceutically acceptable salt thereof is administered to said patient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc